Grandfield & Dodd LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 0.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 82,824 shares of the biopharmaceutical company’s stock after buying an additional 128 shares during the period. Grandfield & Dodd LLC’s holdings in Pfizer were worth $2,805,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Alpha Cubed Investments LLC increased its position in shares of Pfizer by 81.6% in the third quarter. Alpha Cubed Investments LLC now owns 43,964 shares of the biopharmaceutical company’s stock valued at $1,489,000 after buying an additional 19,755 shares in the last quarter. YHB Investment Advisors Inc. increased its position in shares of Pfizer by 2.1% in the third quarter. YHB Investment Advisors Inc. now owns 142,109 shares of the biopharmaceutical company’s stock valued at $4,813,000 after buying an additional 2,981 shares in the last quarter. iAB Financial Bank increased its position in shares of Pfizer by 44.2% in the third quarter. iAB Financial Bank now owns 9,918 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 3,040 shares in the last quarter. Security National Trust Co. increased its position in shares of Pfizer by 5.6% in the third quarter. Security National Trust Co. now owns 105,487 shares of the biopharmaceutical company’s stock valued at $3,572,000 after buying an additional 5,611 shares in the last quarter. Finally, Cohen Lawrence B increased its position in shares of Pfizer by 11.2% in the third quarter. Cohen Lawrence B now owns 8,178 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 68.53% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer Inc. (NYSE:PFE) traded up 1.20% during midday trading on Tuesday, reaching $31.92. 21,642,215 shares of the company’s stock traded hands. The stock has a market capitalization of $193.70 billion, a P/E ratio of 32.05 and a beta of 0.90. The firm’s 50-day moving average price is $31.95 and its 200 day moving average price is $34.15. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.01. The firm earned $13.05 billion during the quarter, compared to analyst estimates of $13.05 billion. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 earnings per share. On average, equities analysts predict that Pfizer Inc. will post $2.41 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.76%. Pfizer’s payout ratio is 106.20%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/29/grandfield-dodd-llc-has-2805000-stake-in-pfizer-inc-pfe.html.

Several brokerages recently weighed in on PFE. Barclays PLC reaffirmed an “equal weight” rating and issued a $34.00 target price on shares of Pfizer in a report on Tuesday, August 2nd. Sanford C. Bernstein set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 2nd. Jefferies Group set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 1st. JPMorgan Chase & Co. set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, August 3rd. Finally, Citigroup Inc. reissued a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, August 3rd. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $37.91.

In other Pfizer news, insider Anthony J. Maddaluna sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total value of $330,000.00. Following the transaction, the insider now directly owns 112,087 shares in the company, valued at approximately $3,698,871. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $30.05, for a total transaction of $552,619.50. Following the completion of the sale, the insider now directly owns 149,199 shares in the company, valued at $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.